Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 1996

View Archived Issues

New agents for CNS disorders claimed by HHS

Beiersdorf-Lilly claims angiotensin II blockers

New cephalosporins from LG Chemical

Dual-action compounds with antiasthma activity reported by Kowa

Medarex claims bispecific reagents for AIDS therapy

British researchers describe anticytokine antisense peptides

Company Profile: Celgene Corporation

Company Profile: Connective Therapeutics

Company Profile: MorphoSys

Company Profile: Shaman Pharmaceuticals

LJP licenses rights to drug for lupus

Further approval for breakthrough glaucoma medication

Andrx licenses chemoprotective agent to Asta

First phase II results for Innapharma's peptide antidepressant

European approval recommended for CMV retinitis Rx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...